Results 61 to 70 of about 22,196 (255)
Acta Medica Indonesiana, 2023 Breast cancer is among the deadliest gynecology cancers in the world. However, the management of advanced-stage breast cancer is often harder as a result of chemoresistance.
Muhammad Yadi Permana +2 more
doaj +2 more sources
Journal of Neuroendocrinology, EarlyView.Abstract During the post‐partum period, new mothers are vulnerable to mood disorders. In adults, impairments in neurogenesis commonly associate with anxiety and depressive behaviors. Insulin‐like growth factor 2 (IGF2) is expressed in the choroid plexus (CP) within the subventricular zone (SVZ) neurogenic niche, and global loss of IGF2 leads to ...
Hollian R. Phillipps +4 more
wiley +1 more source
Endocrine, 2014 Metformin was found to affect plasma levels of some pituitary hormones. This study was aimed at investigating whether metformin treatment has an impact on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired ...
R. Krysiak, J. Okrzesik, B. Okopień
semanticscholar +1 more source
Cochrane Evidence Synthesis and Methods, Volume 3, Issue 4, July 2025.ABSTRACT Background Systematic reviews are essential but time‐consuming and expensive. Large language models (LLMs) and artificial intelligence (AI) tools could potentially automate data extraction, but no comprehensive workflow has been tested for different review types.
T. Helms Andersen +4 more
wiley +1 more source
Indian Journal of Pharmacology, 2014 Objective: To compare the effectiveness and safety of add on therapy of bromocriptine with metformin in type 2 diabetes mellitus (DM) patients. Material and Methods: Adult type 2 DM patients fulfilling the inclusion criteria were randomized in three ...
Arijit Ghosh +5 more
semanticscholar +1 more source
Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
Diabetes Care, 2011 Bromocriptine is a sympatholytic D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on animal and human studies, timed bromocriptine administration within 2 h of awakening is believed to augment low hypothalamic ...
R. DeFronzo
semanticscholar +1 more source
The Nasal–Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases
MedComm, Volume 6, Issue 6, June 2025.Τhe BBB restricts CNS drug delivery. NBDD bypasses the BBB via olfactory/trigeminal routes, enabling CNS delivery of therapeutic (small molecules, biologics, nucleic acids) for neurodegenerative/psychiatric disorders and brain tumors using advanced NBDD delivery systems (e.g nanocarriers) to enhance targeting and bioavailability.
Yi Qiu +7 more
wiley +1 more source
Acta Obstetricia et Gynecologica Scandinavica, Volume 104, Issue 6, Page 1009-1025, June 2025.Our systematic review and meta‐analysis found that subsequent pregnancy after peripartum cardiomyopathy presents significant maternal and fetal risks. This study provides quantification of risks to begin to fill the current evidence gap, however is limited by a paucity of existing data.
Rebecca Man +11 more
wiley +1 more source
Bromocriptine Does Not Alter Speed–Accuracy Tradeoff
Frontiers in Neuroscience, 2012 Being quick often comes at the expense of being accurate. This speed–accuracy tradeoff is a central feature of many types of decision making. It has been proposed that dopamine plays an important role in adjusting responses between fast and accurate ...
J. Winkel +6 more
semanticscholar +1 more source
Bromocriptine, a Dopamine (D2 ) Receptor Agonist, Used Alone and in Combination with Glipizide in Sub–Therapeutic Doses to Ameliorate Hyperglycaemia [PDF]
Journal of Clinical and Diagnostic Research, 2013 Introduction: Bromocriptine, an ergot derivative, is an agonist at the dopamine 2 receptor and a sympatholytic. It is a well established drug in Parkinsonism, hyperprolactinaemia and acromegaly and it has various other clinical indications like ...
Harish Kumar V.S. +5 more
doaj +1 more source